NCT06947213 Orthorexia Nervosa in Postmenopausal Osteoporosis
| NCT ID | NCT06947213 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beylikduzu State Hospital |
| Condition | Osteoporosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 128 participants |
| Start Date | 2025-04-20 |
| Primary Completion | 2025-05-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 128 participants in total. It began in 2025-04-20 with a primary completion date of 2025-05-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A total of 64 female patients diagnosed with osteoporosis based on dual-energy X-ray absorptiometry (DXA) measurements performed within the last six months, and 64 age-matched healthy controls without osteoporosis, will be included in our study. Sociodemographic data such as age, sex, height, weight, and BMI will be recorded. Additionally, information regarding the duration of osteoporosis diagnosis, current treatments, history of fractures, history of falls, comorbidities, and smoking status will be collected. Femoral neck and L1-L4 T-scores and bone mineral density values obtained from existing DXA scans will be documented. Orthorexia nervosa-related symptoms will be assessed using the ORTO-11 scale, mood will be evaluated using the Hospital Anxiety and Depression Scale (HADS), and body image will be assessed using the Body Appreciation Scale-2.
Eligibility Criteria
Inclusion Criteria: * Women between 55-75 years * Women diagnosed with osteoporosis based on DXA measurements performed within the past six months. * Women aged similarly to the osteoporosis group without a diagnosis of osteoporosis (healthy controls). * Willingness to participate and provision of written informed consent. Exclusion Criteria: * Refusal to participate in the study. * Diagnosed psychiatric disorders. * Cognitive impairment. * Presence of malignancy. * Presence of endocrine disorders (e.g., hyperthyroidism, Cushing's syndrome). * Use of glucocorticoids. * Use of medications affecting mood.
Frequently Asked Questions
Who can join the NCT06947213 clinical trial?
This trial is open to female participants only, aged 55 Years or older, up to 75 Years, studying Osteoporosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06947213 currently recruiting?
Yes, NCT06947213 is actively recruiting participants. Visit ClinicalTrials.gov or contact Beylikduzu State Hospital to inquire about joining.
Where is the NCT06947213 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT06947213 clinical trial?
NCT06947213 is sponsored by Beylikduzu State Hospital. The trial plans to enroll 128 participants.